Siolta Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $30M
Latest Deal Amount
  • Investors
  • 8

Siolta Therapeutics General Information

Description

Developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company's therapeutics leverages human infant gut microbiome and clinical data to understand early-life microbial networks that promote healthy gut microbiome development and focuses on decoding these interactions and identifying the specific microbes that promote appropriate gut microbiome development in early life to prevent immune dysfunction and promote healthy development in childhood, enabling medical researchers to harness information from human microbiome studies to treat and prevent inflammatory processes.

Contact Information

Website
www.sioltatherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 930 Brittan Avenue
  • San Carlos, CA 94070
  • United States
+1 (415) 000-0000

Siolta Therapeutics Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Siolta Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 22-Sep-2020 $30M 000.00 0000 Completed Generating Revenue
4. Accelerator/Incubator 10-Apr-2018 00.000 Completed Generating Revenue
3. Accelerator/Incubator 04-Oct-2017 0000 00.000 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Feb-2017 $5M $5M 0000 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Siolta Therapeutics’s complete valuation and funding history, request access »

Siolta Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B1 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 2,000,000 $0.000100 8% $2.5 $2.5 1x $2.5 18.4%
To view Siolta Therapeutics’s complete cap table history, request access »

Siolta Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company's therapeuti
Biotechnology
San Carlos, CA
11 As of 2021
000.00
000 0000-00-00
00000000000 000.00

000000 0

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Brisbane, CA
00 As of 0000
000.00
00000000000 000.00

00000 00

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Siolta Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
00000000 Formerly VC-backed Roseville, MN 00 000.00 000000&0 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Siolta Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Nikole Kimes Ph.D Co-Founder, President, Board Member & Chief Executive Officer
Ricardo Valladares Ph.D Chief Scientific Officer
Susan Lynch Ph.D Co-Founder, Advisor & Board Member
Richard Shames MD Chief Medical Officer
To view Siolta Therapeutics’s complete executive team members history, request access »

Siolta Therapeutics Board Members (5)

Name Representing Role Since
Aleksei Cremo SymBiosis Capital Management Board Member 000 0000
Allison Jeynes-Ellis MD Self Board Member 000 0000
Samir Kaul Khosla Ventures Board Member 000 0000
Susan Lynch Ph.D Siolta Therapeutics Co-Founder, Advisor & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Siolta Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Siolta Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Global Brain Venture Capital Minority 000 0000 000000 0
SymBiosis Capital Management Venture Capital Minority 000 0000 000000 0
Springboard Enterprises Accelerator/Incubator 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority 000 0000 000000 0
Khosla Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial